PT  - JOURNAL ARTICLE
AU  - de Vlas, Sake J.
AU  - Coffeng, Luc E.
TI  - A phased lift of control: a practical strategy to achieve herd immunity against Covid-19 at the country level
AID  - 10.1101/2020.03.29.20046011
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.29.20046011
4099  - http://medrxiv.org/content/early/2020/04/12/2020.03.29.20046011.short
4100  - http://medrxiv.org/content/early/2020/04/12/2020.03.29.20046011.full
AB  - Most countries are affected by the Covid-19 pandemic and experience rapidly increasing numbers of cases and deaths. Many have implemented nationwide stringent control to avoid overburdening the health care system. This paralyzes economic and social activities until the availability of a vaccine, which may take years. We propose an alternative exit strategy to develop herd immunity in a predictable and controllable way: a phased lift of control. This means that successive parts of the country (e.g. provinces) stop stringent control, and Covid-19-related IC admissions are distributed over the country as the whole. Importantly, vulnerable individuals need to be shielded until herd immunity has developed in their area. We explore the characteristics and duration of this strategy using a novel individual-based model for geographically stratified transmission of Covid-19 in a country. The model predicts that individuals will have to experience stringent control for about 14 months on average, but this duration may be significantly shortened by future developments (more IC beds, better drugs). Clearly, the strategy will have a profound impact on individuals and society, and should therefore be considered carefully by various other disciplines (e.g. health systems, ethics, economics) before actual implementation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLEC acknowledges funding from the Dutch Research Council (NWO, grant 016.Veni.178.023).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe source code for the model that was used to simulate data is publicly available (see link). https://www.gitlab.com/luccoffeng/virsim